Bavarian Nordic Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Bavarian Nordic disminuyan a un ritmo anual de 4.2% y 16.2% respectivamente. Se espera que el BPA disminuya en un 23% al año. Se prevé que la rentabilidad financiera sea de 7.1% en 3 años.

Información clave

-10.2%

Tasa de crecimiento de los beneficios

-21.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.6%
Tasa de crecimiento de los ingresos	-3.3%
Rentabilidad financiera futura	7.5%
Cobertura de analistas	Low
Última actualización	06 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

OTCPK:BVNK.F - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	5,202	755	1,737	1,693	3
12/31/2025	5,051	848	1,245	2,024	5
12/31/2024	5,230	659	-80	1,383	4
12/31/2023	7,062	1,475	142	1,119	N/A
9/30/2023	5,906	723	-793	751	N/A
6/30/2023	5,533	1,076	-979	568	N/A
3/31/2023	4,083	301	-1,344	-18	N/A
12/31/2022	3,151	-347	-1,162	220	N/A
9/30/2022	2,404	-599	-1,345	-109	N/A
6/30/2022	1,849	-693	-1,342	-101	N/A
3/31/2022	1,683	-606	-1,477	-215	N/A
12/31/2021	1,898	-465	-1,417	-358	N/A
9/30/2021	1,583	-737	-1,541	-663	N/A
6/30/2021	1,693	-629	-1,279	-478	N/A
3/31/2021	2,022	-368	-727	20	N/A
12/31/2020	1,852	278	-135	572	N/A
9/30/2020	1,914	606	-1,613	981	N/A
6/30/2020	1,499	481	-1,970	623	N/A
3/31/2020	901	267	-2,427	227	N/A
12/31/2019	662	-347	-2,947	-276	N/A
9/30/2019	554	-402	-645	-262	N/A
6/30/2019	631	-271	-529	-204	N/A
3/31/2019	616	-279	-408	-152	N/A
12/31/2018	501	-362	-500	-289	N/A
9/30/2018	360	-445	-647	-467	N/A
6/30/2018	873	-151	-706	-564	N/A
3/31/2018	1,184	5	-258	-158	N/A
12/31/2017	1,370	181	137	216	N/A
9/30/2017	1,745	453	N/A	1,030	N/A
6/30/2017	1,463	225	N/A	880	N/A
3/31/2017	1,182	153	N/A	501	N/A
12/31/2016	1,007	31	N/A	268	N/A
9/30/2016	909	-54	N/A	-539	N/A
6/30/2016	536	-202	N/A	-345	N/A
3/31/2016	808	-115	N/A	-561	N/A
12/31/2015	1,021	59	N/A	105	N/A
9/30/2015	1,244	155	N/A	818	N/A
6/30/2015	1,390	186	N/A	815	N/A
3/31/2015	1,166	70	N/A	1,018	N/A
12/31/2014	1,217	26	N/A	339	N/A
9/30/2014	1,013	-99	N/A	-63	N/A
6/30/2014	1,107	-61	N/A	-105	N/A
3/31/2014	1,293	-12	N/A	180	N/A
12/31/2013	1,213	-47	N/A	147	N/A
9/30/2013	1,142	-82	N/A	32	N/A
6/30/2013	1,127	-81	N/A	160	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: BVNK.F's earnings are forecast to decline over the next 3 years (-10.2% per year).

Beneficios vs. Mercado: BVNK.F's earnings are forecast to decline over the next 3 years (-10.2% per year).

Beneficios de alto crecimiento: Se prevé que los beneficios de BVNK.F disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de BVNK.F disminuyan en los próximos 3 años (-4.2% al año).

Ingresos de alto crecimiento: BVNK.F's revenue is forecast to decline over the next 3 years (-3.3% per year).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BVNK.F sea baja dentro de 3 años (7.1%).

Bavarian Nordic Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Recent updates

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Bavarian Nordic to Supply Smallpox Vaccines to Three European Countries

Bavarian Nordic A/S Announces Top-line Results from Phase 2 Clinical Trial of BN-Brachyury in Chordoma

Bavarian Nordic A/S Secures Second Part of Smallpox Vaccine Order from the U.S. Government

Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses

Bavarian Nordic A/S to Report Q2, 2021 Results on Aug 25, 2021

Bavarian Nordic A/S Announces Appointment of Anu Helena Kerns as Executive Vice President, People and Organization, Effective from November 2020

Bavarian Nordic A/S to Report Fiscal Year 2020 Results on Mar 12, 2021

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento